Table 1.
Patient characteristicsa
| Characteristic | Continued thienopyridine (n = 5862) | Placebo (n = 5786) |
|---|---|---|
| Patients | ||
| Age (years) | 61.4 ± 10.3 | 61.2 ± 10.3 |
| Female sex | 1457 (24.9) | 1468 (25.4) |
| Non-White Raceb | 500 (8.7) | 480 (8.5) |
| Hispanic or Latino ethnic groupb | 199 (3.5) | 207 (3.6) |
| Weight (kg) | 91.0 ± 19.6 | 91.1 ± 19.4 |
| Body mass indexc | 30.4 ± 5.7 | 30.4 ± 5.8 |
| Diabetes mellitus | 1737 (29.8) | 1654 (28.7) |
| Hypertension | 4330 (74.1) | 4192 (72.6) |
| Cigarette smoker | 1582 (27.4) | 1560 (27.4) |
| Stroke or TIA | 198 (3.4) | 203 (3.5) |
| Congestive heart failure | 273 (4.7) | 251 (4.4) |
| Peripheral arterial disease | 319 (5.5) | 330 (5.8) |
| Renal insufficiency/failure | 251 (4.3) | 217 (3.8) |
| Prior myocardial infarction | 1252 (21.7) | 1204 (21.1) |
| Prior cancer | 547 (9.4) | 523 (9.1) |
| Indication for Index PCI | ||
| STEMI | 845 (14.4) | 835 (14.4) |
| NSTEMI | 960 (16.4) | 936 (16.2) |
| Unstable anginad | 915 (15.6) | 906 (15.7) |
| Stable angina | 2081 (35.5) | 2068 (35.7) |
| Other | 1061 (18.1) | 1041 (18.0) |
| Thienopyridine at randomization | ||
| Clopidogrel | 4008 (68.4) | 3954 (68.3) |
| Prasugrel | 1854 (31.6) | 1832 (31.7) |
| Type of stent at index procedure | ||
| Drug eluting | 5020 (85.6) | 4941 (85.4) |
| Bare metal | 842 (14.4) | 845 (14.6) |
CABG, coronary-artery bypass grafting; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischaemic attack.
aPlus–minus values are means ± SD; all other numbers are n (%). There were no significant differences between the two groups. For most variables, <2% of patients had missing values.
bRace and ethnic groups were self-reported.
cBody-mass index is the weight in kilograms divided by the square of the height in meters.
dIncludes unstable angina without reported elevation of cardiac enzymes.